Isabelle Ray‐Coquard

Author

Also Known As

Alexandre da Costa, D. Nevell, E. Lecointe, Eric Pujade-Lauraine, I Ray-Coquard, I. Ray-Coquard, I. Ray-coquard, ISABELLE RAY-COQUARD, Ignacio Romero, Isabelle L. Ray-Coquard

1.1K

Publications

43K

Citations

104

H-Index

141

Concepts

All Affiliations

Centre Léon Bérard Université Claude Bernard Lyon 1 Institut Gustave Roussy Inserm Institut Bergonié

About

Isabelle Ray‐Coquard is an author at Centre Léon Bérard specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	52	121	16.9K
2	Health Sciences	13	17	712
3	Public Health	10	11	834
4	Engineering	1	1	16
5	Nursing	1	1	15

Isabelle Ray‐Coquard

256

Publications

30.8K

Citations

H-Index

Page 1

	Year	Citations
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, New England Journal of Medicine	2019	1.9K
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, The Lancet Oncology Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets	2017	1.8K
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial Éric Pujade-Lauraine, Felix Hilpert, B. Weber, Journal of Clinical Oncology	2014	1.6K
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials Andreas du Bois, Eric Pujade‐Lauraine, Philipp Harter, Cancer	2009	1.6K
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, The Lancet Oncology MedicinePharmacologyPathologyCancer TreatmentOncology	2016	1.2K
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease Nicoletta Colombo, Cristiana Sessa, Andreas du Bois, Annals of Oncology Borderline TumoursTumoral PathologyMedicinePathologyGynecology	2019	1.1K
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas Isabelle Ray‐Coquard, Claire Cropet, M. van Glabbeke, Cancer Research	2009	780
Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome Michael Gobert, Isabelle Treilleux, Nathalie Bendriss‐Vermare, Cancer Research	2009	731
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study Thomas Bachelot, C. Bourgier, Claire Cropet, Journal of Clinical Oncology	2012	707
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study Nicolas Penel, Binh Bui, Jacques‐Olivier Bay, Journal of Clinical Oncology	2008	683

Page 1